Independent monitors have paused enrollment in a study testing the COVID-19 antiviral drug remdesivir plus an experimental antibody therapy being developed by Eli Lilly that’s similar to a treatment President Donald Trump recently received. Lilly confirmed Tuesday that the study had been paused “out of an abundance of caution” and said safety is its top concern. The company would not say more about what led to this step.